Meryem Khadija Talbo

Meryem Khadija Talbo

Auto-generated profile, based on publicly available information

Meryem Khadija Talbo


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2022 in Canadian Journal of Diabetes
Verified
Journal Article
Closed access
ABAnne-Sophie Brazeau
Anne-Sophie Brazeau
VMVirginie Messier
Virginie Messier
MTMeryem K. Talbo
Meryem K. Talbo
CGClaudia Gagnon
Claudia Gagnon
NTNadine Taleb
Nadine Taleb
RRRémi Rabasa-Lhoret
Rémi Rabasa-Lhoret

4 August 2023 in eClinicalMedicine
Verified
Journal Article
Open access
MTMeryem K. Talbo
Meryem K. Talbo
AKAlexandra Katz
Alexandra Katz
LHLee Hill
Lee Hill
TPTricia M. Peters
Tricia M. Peters
JYJean-François Yale
Jean-François Yale
ABAnne-Sophie Brazeau
Anne-Sophie Brazeau
Fear of hypoglycaemia (FOH) significantly disrupts the daily management of type 1 diabetes (T1D) and increases the risk of complications. Recent technological advances can improve glucose metrics and reduce hypoglycaemia frequency, yet their impact on FOH is unclear. This systematic review and meta-analysis (SRMA) aimed to synthesize the current literature to understand the impact of diabetes technologies on FOH in T1D. In this SRMA, we searched PubMed, Medline, Scopus, and Web of Science from inception up to May 21st, 2023 for studies assessing the effect of using real-time or intermittently scanned continuous glucose monitors (rtCGM or isCGM); insulin pumps (CSII); and their combinations on FOH as the primary outcome, measured using the Hypoglycaemia Fear Survey (HFS; including total, worries [HFS-W], and behaviours [HFS-B] scores), in non-pregnant adults with T1D. Data was extracted by the first and second authors. Results were pooled using a random-effects model based on study design (RCT and non-RCT), with subgroup analysis based on the type of technology, reported change in hypoglycaemia frequency, and duration of use. Risk of bias was evaluated with Cochrane and Joanna Briggs Institute tools. This study is registered with PROSPERO, CRD42021253618. A total of 51 studies (n = 8966) were included, 22 of which were RCTs. Studies on rtCGM and CSII reported lower FOH levels with ≥8 weeks of use. Studies on CSII and rtCGM combinations reported lower FOH levels after ≥13 weeks of automated insulin delivery (AID) use or 26 weeks of sensor-augmented pump (SAP) use. The meta-analysis showed an overall lower FOH with technologies, specifically for the HFS-W subscale. The RCT meta-analysis showed lower HFS-W scores with rtCGM use (standard mean difference [95%CI]: -0.14 [-0.23, -0.05], I2 = 0%) and AID (-0.17 [-0.33, -0.01], I2 = 0%). Results from non-RCT studies show that SAP users (-0.33 [-0.38, -0.27], I2 = 0%) and rtCGM users (-0.38 [-0.61, -0.14], I2 = 0%) had lower HFS-W. We found consistent, yet small to moderate, effects supporting that diabetes technologies (specifically rtCGM, SAP, and AID) may reduce hypoglycaemia-related worries in adults with T1D. Current literature, however, has limitations including discrepancies in baseline characteristics and limited, mainly descriptive, statistical analysis. Thus, future studies should assess FOH as a primary outcome, use validated surveys, and appropriate statistical analysis to evaluate the clinical impacts of technology use beyond just glucose metrics. Canadian Institutes of Health Research, Juvenile Diabetes Research Foundation Ltd.

3 March 2022 in Canadian Journal of Diabetes
Verified
Journal Article
Closed access
MTMeryem Khadija Talbo
Meryem Khadija Talbo
AKAlexandra Katz
Alexandra Katz
MDMichel Dostie
Michel Dostie
LLLaurent Legault
Laurent Legault
ABAnne-Sophie Brazeau
Anne-Sophie Brazeau

28 August 2024 in Diabetes/Metabolism Research and Reviews
Verified
Journal Article
Open access
MLMarie‐Laure Lalanne‐Mistrih
Marie‐Laure Lalanne‐Mistrih
ABAnne Bonhoure
Anne Bonhoure
VMVirginie Messier
Virginie Messier
VBValérie Boudreau
Valérie Boudreau
MLMaha Lebbar
Maha Lebbar
RRRémi Rabasa‐Lhoret
Rémi Rabasa‐Lhoret
Aims: The prevalence and associations of overweight and obesity in Canadian adult people living with type 1 diabetes (PWT1D) are poorly documented. In a cohort of PWT1D patients, this study assesses (i) overweight and obesity frequencies and associated PWT1D clinicodemographic characteristics, (ii) diabetes characteristics, and (iii) the use of noninsulin adjunctive agents.Materials and Methods: Cross‐sectional analysis of self‐reported data from the BETTER registry: 1091 adult PWT1D (aged 44.4 ± 15.0 years; 32% HbA1c<7% [53 mmol/mol]) classified by BMI classes: underweight combined with normal weight, overweight, or obesity. Bivariate analyses were used to identify associations between BMI classes, diabetes characteristics, complications, and treatments.Results: Overweight and obesity affected 34.6% and 19.8% of participants. Compared to underweight + normal weight, PWT1D with overweight/obesity was associated with male sex, higher age, lower education level, longer diabetes duration, and higher total insulin doses and use of cardiorenal therapies (all p < 0.001). Compared to other PWT1D, those living with obesity reported higher HbA1c (p < 0.05), less frequent hypoglycemia (p < 0.05), more cardiovascular diseases (p < 0.003), retinopathy, neuropathy, depression treatment as well as noninsulin adjunctive agent use (all p < 0.001). Logistic regression showed that living with overweight/obesity was associated with male sex, being treated for cardiorenal therapies, depression, diabetes duration, and total daily insulin doses.Conclusions: Overweight or obesity affects over half of adult PWT1D in the Canadian BETTER registry and is associated with higher HbA1c levels, higher total daily insulin doses, more chronic diabetes complications and noninsulin adjunctive agent use, a worse cardiometabolic profile, and lower hypoglycemia frequency.

7 July 2023 in Diabetes Research and Clinical Practice
Verified
Journal Article
Closed access
MTMeryem K Talbo
Meryem K Talbo
MLMaha Lebbar
Maha Lebbar
ZWZekai Wu
Zekai Wu
AVAndréane Vanasse
Andréane Vanasse
MLMarie-Laure Lalanne-Mistrih
Marie-Laure Lalanne-Mistrih
RRRemi Rabasa-Lhoret
Remi Rabasa-Lhoret

6 September 2023 in PLOS Climate
Verified
Journal Article
Open access
PDF file
PCPaige Cheveldayoff
Paige Cheveldayoff
FCFariha Chowdhury
Fariha Chowdhury
NSNyah Shah
Nyah Shah
CBCarly Burow
Carly Burow
MFMelanie Figueiredo
Melanie Figueiredo
LHLee Hill
Lee Hill
The ability to regulate core body temperature is a critical factor in avoiding occupational heart stress in demanding environments. Heat-related illness in an occupational setting is complex and multifactorial and includes environment (intrinsic and extrinsic), the occupational clothing requirements and physiological factors. Much of this research began in the gold mines in South Africa after several miners died due to heat related illness. Similar research was conducted during World War Two and was crucial for the creation of acclimatization techniques and strategies for acquiring thermal tolerance. Techniques such as fatigue recovery and body cooling are still used today to prevent heat related illness in individuals with occupations that have frequent exposure to heat and high physical loads. These individuals are at greater risk of heat related illness as extended exposure to a hot or humid environment in combination with strenuous physical activity can overwhelm the body’s homeostatic cooling mechanisms. In addition, individuals from special populations with chronic or acute health impacts such as diabetes mellitus, also have a greater risk for the aforementioned. Currently, there are several heat prevention strategies, including training and education, regulation and monitoring, in place to protect workers from heat related illness and casualty. These strategies, along with future considerations and the impact of climate change will be highlighted in this review.